Literature DB >> 23682017

Warfarin pharmacogenomics in children.

Susan I Vear1, C Michael Stein, Richard H Ho.   

Abstract

Warfarin is the most commonly used oral anticoagulant worldwide. Warfarin has a narrow therapeutic index, requiring frequent monitoring of the INR to achieve therapeutic anticoagulation. The role of pharmacogenomics in warfarin disposition and response has been well established in adults, but remains unclear for pediatric patients. In this review, we focus on the important CYP2C9 and VKORC1 variants involved in warfarin response, our current understanding of warfarin disposition and pharmacogenomics, and recent warfarin pharmacogenetic studies in pediatric patients. Finally, we discuss the need for future pediatric studies and the clinical implications of developing pharmacogenetic-based dosing algorithms in children.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CYP2C9; VKORC1; pharmacogenomics; warfarin

Mesh:

Substances:

Year:  2013        PMID: 23682017      PMCID: PMC3786327          DOI: 10.1002/pbc.24592

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  39 in total

1.  Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.

Authors:  Yuya Kato; Fukiko Ichida; Kazuyoshi Saito; Kazuhiro Watanabe; Keiichi Hirono; Toshio Miyawaki; Naoki Yoshimura; Isao Horiuchi; Masato Taguchi; Yukiya Hashimoto
Journal:  Drug Metab Pharmacokinet       Date:  2011-01-25       Impact factor: 3.614

2.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

3.  VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Authors:  Tina T Biss; Peter J Avery; Leonardo R Brandão; Elizabeth A Chalmers; Michael D Williams; John D Grainger; Julian B S Leathart; John P Hanley; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

4.  Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Authors:  Inna Y Gong; Rommel G Tirona; Ute I Schwarz; Natalie Crown; George K Dresser; Samantha Larue; Nicole Langlois; Alejandro Lazo-Langner; Guangyong Zou; Dan M Roden; C Michael Stein; Marc Rodger; Marc Carrier; Melissa Forgie; Philip S Wells; Richard B Kim
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

5.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Authors:  Nita A Limdi; Mia Wadelius; Larisa Cavallari; Niclas Eriksson; Dana C Crawford; Ming-Ta M Lee; Chien-Hsiun Chen; Alison Motsinger-Reif; Hersh Sagreiya; Nianjun Liu; Alan H B Wu; Brian F Gage; Andrea Jorgensen; Munir Pirmohamed; Jae-Gook Shin; Guilherme Suarez-Kurtz; Stephen E Kimmel; Julie A Johnson; Teri E Klein; Michael J Wagner
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

6.  In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

Authors:  Ulrike Nowak-Göttl; Kevin Dietrich; Daria Schaffranek; Noha Sharaf Eldin; Yutaka Yasui; Christof Geisen; Lesley G Mitchell
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

Review 7.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

Review 8.  Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Authors:  Thomas P Moyer; Dennis J O'Kane; Linnea M Baudhuin; Carmen L Wiley; Alexandre Fortini; Pamela K Fisher; Denise M Dupras; Rajeev Chaudhry; Prabin Thapa; Alan R Zinsmeister; John A Heit
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 9.  Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.

Authors:  Limei Yang; Weihong Ge; Feng Yu; Huaijun Zhu
Journal:  Thromb Res       Date:  2009-11-25       Impact factor: 3.944

Review 10.  Polymorphisms of human cytochrome P450 2C9 and the functional relevance.

Authors:  Shu-Feng Zhou; Zhi-Wei Zhou; Min Huang
Journal:  Toxicology       Date:  2009-08-26       Impact factor: 4.221

View more
  5 in total

1.  The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Authors:  Susan I Vear; Gregory D Ayers; Sara L Van Driest; Robert F Sidonio; Charles Michael Stein; Richard H Ho
Journal:  Br J Haematol       Date:  2014-03-06       Impact factor: 6.998

2.  Pharmacogenomics in Children.

Authors:  Michael J Rieder; Abdelbaset A Elzagallaai
Journal:  Methods Mol Biol       Date:  2022

3.  Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models.

Authors:  Elizabeth Marek; Jeremiah D Momper; Ronald N Hines; Cheryl M Takao; Joan C Gill; Vera Pravica; Andrea Gaedigk; Gilbert J Burckart; Kathleen A Neville
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

Review 4.  Pharmacogenomics and adverse drug reactions in children.

Authors:  Michael J Rieder; Bruce Carleton
Journal:  Front Genet       Date:  2014-04-16       Impact factor: 4.599

Review 5.  Warfarin: The End or the End of One Size Fits All Therapy?

Authors:  Munir Pirmohamed
Journal:  J Pers Med       Date:  2018-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.